What is cancer? A focus on Grade Group 1 prostate cancer

Since the widespread adoption of prostate‐specific antigen‐based screening for prostate cancer, the prevalence of Grade Group 1 (GG1) prostate cancer has risen. Historically, these patients were subjected to overtreatment of this otherwise indolent disease process, leading to significant quality‐of‐...

Full description

Saved in:
Bibliographic Details
Published in:BJU international 2024-04, Vol.133 (4), p.360-364
Main Authors: Talwar, Ruchika, Akinsola, Olutiwa, Penson, David F.
Format: Article
Language:English
Subjects:
active surveillance
Adenocarcinoma
epidemiology
Gleason 6 prostate cancer
Grade Group 1 prostate cancer
Humans
low‐grade disease
Male
Morbidity
Neoplasm Grading
Prostate cancer
Prostate-Specific Antigen
Prostatic Neoplasms - diagnosis
Prostatic Neoplasms - genetics
Prostatic Neoplasms - therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Since the widespread adoption of prostate‐specific antigen‐based screening for prostate cancer, the prevalence of Grade Group 1 (GG1) prostate cancer has risen. Historically, these patients were subjected to overtreatment of this otherwise indolent disease process, leading to significant quality‐of‐life detriments. Active surveillance as a primary management strategy has allowed for a focus on early detection while minimising morbidity from unnecessary intervention. Here we provide a comprehensive overview of the characteristics of GG1 prostatic adenocarcinoma, including its histological features, genomic differentiators, clinical progression, and implications for treatment guidelines, all supporting the movement to reclassify GG1 disease as a non‐cancerous entity.
ISSN:1464-4096
1464-410X
DOI:10.1111/bju.16280